Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

INTRODUCTION: We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to phase I clinical trials. METHODS: Patients with cervical cancer who received at least one dose of a phase I investigational agent a...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Ji, Lin, Heather Y., Fu, Siqing, Biter, Amadeo B., Dumbrava, Ecaterina E., Karp, Daniel D., Naing, Aung, Pant, Shubham, Piha-Paul, Sarina A., Rodon, Jordi, Subbiah, Vivek, Tsimberidou, Apostolia M., Yap, Timothy A., Frumovitz, Michael M., Jazaeri, Amir A., Ramirez, Pedro T., Westin, Shannon N., Yuan, Ying, Meric-Bernstam, Funda, Hong, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888522/
https://www.ncbi.nlm.nih.gov/pubmed/36751659
http://dx.doi.org/10.36401/JIPO-22-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888522/
https://www.ncbi.nlm.nih.gov/pubmed/36751659
http://dx.doi.org/10.36401/JIPO-22-23

Ejemplares similares